Cytokinetics Fundamentals

CYTK
 Stock
  

USD 50.81  0.02  0.0393%   

Cytokinetics fundamentals help investors to digest information that contributes to Cytokinetics' financial success or failures. It also enables traders to predict the movement of Cytokinetics Stock. The fundamental analysis module provides a way to measure Cytokinetics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cytokinetics stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  
Cytokinetics Selling General and Administrative Expense is increasing as compared to previous years. The last year's value of Selling General and Administrative Expense was reported at 96.8 Million.

Cytokinetics Shares Owned by Insiders Analysis

Cytokinetics' Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Insiders Shares 
 = 
Executives Shares 
Employees 
More About Shares Owned by Insiders | All Equity Analysis

Current Cytokinetics Shares Owned by Insiders

    
  4.45 %  
Most of Cytokinetics' fundamental indicators, such as Shares Owned by Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytokinetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Compare to competition

Based on the latest financial disclosure, 4.45% of Cytokinetics are shares owned by insiders. This is 70.69% lower than that of the Healthcare sector and 68.62% lower than that of the Biotechnology industry. The shares owned by insiders for all United States stocks is 55.9% higher than that of the company.

Cytokinetics Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Cytokinetics's current stock value. Our valuation model uses many indicators to compare Cytokinetics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cytokinetics competition to find correlations between indicators driving Cytokinetics's intrinsic value. More Info.
Cytokinetics is number one stock in price to book category among related companies. It is the top company in revenue category among related companies totaling about  3,841,110  of Revenue per Price to Book. Cytokinetics Revenues is increasing as compared to previous years. The last year's value of Revenues was reported at 70.43 Million. Comparative valuation analysis is a catch-all model that can be used if you cannot value Cytokinetics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cytokinetics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cytokinetics' earnings, one of the primary drivers of an investment's value.

Cytokinetics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Cytokinetics from analyzing Cytokinetics' financial statements. These drivers represent accounts that assess Cytokinetics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cytokinetics' important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(932.77 K)(817.61 K)(780.08 K)(689.9 K)(586.69 K)(633 K)
Revenue Per Employee97.58 K242.31 K172.23 K302.58 K191.9 K212.66 K
Average Assets306.78 M242.16 M218.51 M374.25 M702.56 M758.02 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(122.85 M)(101.25 M)(113.78 M)(109.5 M)(196.6 M)(201.77 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(122.85 M)(101.25 M)(113.78 M)(109.5 M)(196.6 M)(201.77 M)
Earnings before Tax(127.79 M)(106.29 M)(121.69 M)(127.29 M)(215.31 M)(220.98 M)
Average Equity131.82 M63.19 M(8.08 M)34.8 M144.3 M116.66 M
Enterprise Value353.14 M360.05 M639.82 M1.41 B3.99 B4.3 B
Free Cash Flow(104.64 M)(102.09 M)(93.53 M)(2.11 M)(191.39 M)(196.43 M)
Invested Capital168.94 M189.91 M363.43 M558.56 M926.72 M999.89 M
Invested Capital Average203.78 M194.17 M230.69 M388.78 M814.76 M879.08 M
Market Capitalization439.16 M345.77 M626.86 M1.47 B3.82 B4.13 B
Tangible Asset Value294.81 M211.18 M289.81 M533.8 M841.32 M907.74 M
Working Capital241.85 M185.48 M207.73 M443.02 M463.81 M500.43 M

Cytokinetics Fundamentals

About Cytokinetics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cytokinetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytokinetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytokinetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Last ReportedProjected for 2022
Deferred Revenue100 M107.9 M
Revenues70.4 M59.3 M
Revenue to Assets 0.08  0.09 
Revenue Per Employee191.9 K212.7 K
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people.

Cytokinetics Investors Sentiment

The influence of Cytokinetics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Cytokinetics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Cytokinetics' public news can be used to forecast risks associated with investment in Cytokinetics. The trend in average sentiment can be used to explain how an investor holding Cytokinetics can time the market purely based on public headlines and social activities around Cytokinetics. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Cytokinetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Cytokinetics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Cytokinetics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Cytokinetics.

Cytokinetics Implied Volatility

    
  236.27  
Cytokinetics' implied volatility exposes the market's sentiment of Cytokinetics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Cytokinetics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Cytokinetics stock will not fluctuate a lot when Cytokinetics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cytokinetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cytokinetics' short interest history, or implied volatility extrapolated from Cytokinetics options trading.

Pair Trading with Cytokinetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.

Moving against Cytokinetics

0.66KZIAKazia Therapeutics Fiscal Year End 6th of October 2022 PairCorr
The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Cytokinetics Piotroski F Score and Cytokinetics Altman Z Score analysis. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Bond Directory
Find actively traded corporate debentures issued by US companies
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.8 B
Quarterly Revenue Growth YOY
30.29
Return On Assets
-0.17
Return On Equity
-3.38
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.